Biomedical Engineering Reference
In-Depth Information
100. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley
JL. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an
HIV protease inhibitor. Pharm Res 16: 1206-1212.
101. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen JH, Schinkel AH.
2001. P-Glycoprotein limits oral availability, brain, and fetal penetration of saquinavir
even with high-doses of ritonavir. Mol Pharmacol 59: 806-813.
102. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. 1999. Interactions of HIV protease
inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56: 383-389.
103. Ding R, Tayrouz Y, Riedel KD, Burhenn J, Weiss J, Mikus G, Haefeli WE. 2004. Sub-
stantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers.
Clin Pharmacol Ther 76: 73-84.
104. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D,
Markowitz M, Follansbee S, et al. 1999. Ritonavir and saquinavir combination therapy
for the treatment of HIV infection. AIDS 13: 213-224.
105. Kaufmann GR, Duncombe C, Cunningham P, Beveridge A, Carr A, Sayer D, French M,
Cooper DA. 1998. Treatment response and durability of a double protease inhibitor ther-
apy with saquinavir and ritonavir in an osbervational cohort of HV-1-infected individuals.
AIDS 12: 1625-1630.
106. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. 1996. Cytochrome P450-mediated
metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver micro-
somes. J Pharmacol Exp Ther 277: 423-431.
107. Hebert MF, Lam AY. 1999. Diltiazem increases tacrolimus concentrations. Ann Pharma-
cother 33: 680-682.
108. Arima H, Yunomae K, Hirayama F, Uekama K. 2001. Contribution of P-glycoprotein to
the enhancing effects of dimethyl-
-cyclodextrin on oral bioavailability of tacrolimus.
J Pharmacol Exp Ther 297: 547-555.
109. Hashimoto Y, Sasa H, Shimomura M, Inui K. 1998. Effects of intestinal and hepatic
metabolism on the bioavailability of tacrolimus in rats. Pharm Res 15: 1609-1613.
110. Sipe BE, Jones RJJ, Bokhart GH. 2003. Rhabdomyolysis causing AV blockade due to
possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother
37: 808-811.
111. Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH,
Beijnen JH. 2006. Determinants of the elimination of methotrexate and 7-hydroxy-
methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Phar-
macol 62(1): 71-80.
112. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. 2000. P-Glycoprotein inhibitor
erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol
Ther 38: 161-167.
113. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, R osch W, Langguth P. 1996.
Evidence for intestinal secretion as an additional clearance pathway of talinolol enan-
tiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res
13: 514-522.
114. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A,
Langguth P. 1998. P-Glycoprotein transporters and the gastrointestinal tract: evaluation
of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Int J Clin Pharmacol Ther 36: 16-24.
Search WWH ::
Custom Search